Brief: Bellicum Pharmaceuticals Licenses Its CaspaCIDe Safety Switch To MD Anderson
11/12/2019 12:40
Dec 11 (Reuters) - Bellicum Pharmaceuticals Inc BLCM.O :
* BELLICUM PHARMACEUTICALS LICENSES ITS CASPACIDE® SAFETY
SWITCH
TO MD ANDERSON
* BELLICUM PHARMACEUTICALS INC - MD ANDERSON'S DECISION TO
EXERCISE OPTION ENTITLED BELLICUM TO RECEIVE AN UPFRONT PAYMENT
OF $5 MILLION
* BELLICUM PHARMACEUTICALS INC - UPFRONT PAYMENT OF $5
MILLION
WILL BE RECOGNIZED IN Q4 2019 RESULTS
Source text for Eikon: ID:nGNX8C5q6G
Further company coverage: BLCM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bellicum Pharmaceuticals
See all newsBrief: Bellicum Pharmaceuticals- In Connection With Dissolution And Plan Of Dissolution, On February 23, Richard A. Fair Resigned As President And Co's CEO
Brief: Bellicum Pharmaceuticals Says Board Approved Liquidation And Dissolution Of Co In Connection With Approval Of Asset Purchase Agreement
Brief: Bellicum Pharmaceuticals Initiated A 12 Stock Split On Dec 8, 2022
Brief: Bellicum Reports Third Quarter 2022 Financial Results And Provides Operational Update
Bellicum Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview